Skip to content

Author

N. Tung

We have 3 of 42 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial

Given the heterogeneity of HER2-positive breast cancer, reliable biomarkers to guide treatment are needed. We conducted multi-platform biomarker analyses of baseline tumor tissue from the DAPHNe trial of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) for HER2-positive early breast cancer to characterize inter- and...

Emily L. Chen, I. Schlam, Kenichi Shimada et al. · 0 citations
Open access Aug 2026

Pathologic complete response (pCR) rate and factors associated with pCR after taxane, trastuzumab, and pertuzumab in HER2-positive breast cancer: secondary analyses of EA1181

Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER− and one-third with HER2+/ER+ breast cancer, and these findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.

N. Tung, Feng-Min Zhao, A. DeMichele et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.